ProBioGen has announced a multi-product commercial licence agreement with AstraZeneca to use the GlymaxX technology, ProBioGen said in a statement.
Following evaluation of the technology under a research license, AstraZeneca will now continue to use GlymaxX, and will integrate the technology into their drug discovery, it further said.
It also noted that GlymaxX improves target cell killing orchestrated by natural killer cells, thereby enhancing Antibody-Dependent Cell-mediated Cytotoxicity (ADCC). It is a universal and simple technology that allows modifying the existing cell lines or creating new ones, demonstrating its flexibility. Another unique advantage of GlymaxX is that it allows using the same modified cell line to produce antibodies of varying levels of fucosylation.